E2A (ALL) PBX1: T(1;19), HEPARIN BLOOD

image not found

NABL Cap Accredited    
This test detects the E2A–PBX1 fusion gene resulting from the t(1;19) chromosomal translocation, commonly associated with certain subtypes of acute lymphoblastic leukemia (ALL). Identifying this genetic abnormality helps in confirming diagnosis and assessing prognosis. The test also supports clinicians in planning targeted treatment and monitoring disease progression. Metropolis Healthcare performs this analysis using advanced molecular techniques for highly accurate detection

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 4,135.00

Sample Type: Sodium Heparin Blood

Fasting Not Required


Notes: T0004

Frequently Asked Questions (FAQ's):

What does the E2A PBX1 test detect?
It identifies the t(1;19) translocation that produces the E2A–PBX1 fusion gene in ALL.

Why is this test important?
It helps diagnose specific subtypes of acute lymphoblastic leukemia and provides prognostic insight.

Do I need any preparation before the test?
No special preparation is required for a heparin blood sample.

Who should undergo this test?
Patients suspected or confirmed with ALL who need further genetic characterization.

How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses advanced molecular assays such as PCR-based techniques to detect the fusion gene accurately.

Can this test guide treatment decisions?
Yes, identifying this mutation helps clinicians tailor therapy and assess treatment response.

Is this test useful for monitoring disease?
It may aid in detecting minimal residual disease when clinically recommended.

Are Metropolis Healthcare results reliable?
Yes, the results are highly dependable due to stringent quality control and validated molecular workflows

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab